ClinicalTrials.gg
CompletedNCT05611671EMERALD-2Updated Oct 15, 2026Results posted

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

A Phase 2 interventional study of MORF-057 and Placebo in Inflammatory Bowel Diseases and Colitis, Ulcerative, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). Completed at 102 sites in 21 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionColitis, UlcerativeRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colitis, Ulcerative
Why
  1. The study's listed conditions name Colitis, Ulcerative, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Colitis, Ulcerative by Eli Lilly and Company — 5 open to participants now, 7 under way, 3 of them phase 3. Colitis, Ulcerative · Eli Lilly and Company.

Enrollment
6th of 16
280 · median 211
Started
2022
with 1 other
Phase 2
8 of 16
3 open now
Registered
9th of 16
by date

Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 6th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 2, and was the 9th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 16 studies in Colitis, Ulcerative by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Colitis, Ulcerative by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).

Read the detailed description

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three active dose regimens of MORF-057 plus a placebo regimen in study participants with moderately to severely active UC. After completion of the 12-week Induction Period, participants may be switched to a different active MORF-057 regimen during the Maintenance Period. Those randomized into the placebo group in the Induction Period will be switched to receive an active MORF-057 regimen during the Maintenance Period.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Colitis, Ulcerative

Browse trials for

Keywords

  • Ulcerative Colitis (UC)
  • Inflammatory Bowel Disease (IBD)
  • a4b7
  • Moderate-to-severe
  • Integrin
  • EMERALD
04

In context

Colitis, Ulcerative Reclassified

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

This study's enrollment of 280 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.

Browse Colitis, Ulcerative studies →

Lead sponsor

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company.

Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has signs/symptoms of moderate to severe UC for at least 3 months prior to Screening
  • Has evidence of UC extending at least 15 cm from the anal verge
  • Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, or balsalazide), , (e.g., azathioprine, 6-mercaptopurine, or methotrexate), advanced therapies for UC (e.g., biologic agents, Janus kinase [JAK] antagonists, or sphingosine-1-phosphate [S1P] receptor agonists)
  • Subject has no prior exposure to approved or anti-integrin therapies
  • Agrees to abide by the study guidelines and requirements
  • Capable of giving signed

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn's disease
  • Has positive findings on a subjective neurological screening questionnaire
  • Has a concurrent, , serious, unstable comorbidity
  • Previous treatment with vedolizumab or other licensed or integrin inhibitors
  • Participation in any other interventional study or received any investigational therapy within 30 days
  • Previous exposure to MORF-057 and/or a known to drugs with a similar mechanism to MORF-057
  • Unable to attend study visits or comply with study procedures
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    MORF-057 200 mg BID

    Participants received a 200 milligram (mg) oral dose of MORF-057 twice daily (BID) for 12 weeks.

    Drug: MORF-057

  • Experimental
    MORF-057 100 mg BID

    Participants received a 100 mg oral dose of MORF-057 twice daily for 12 weeks.

    Drug: MORF-057

  • Experimental
    MORF-057 100 mg QD-M

    Participants received a 100 mg oral dose of MORF-057 once daily in the morning (QD-M) for 12 weeks.

    Drug: MORF-057

  • Placebo comparator
    Placebo

    Participants received an oral dose of matching placebo for 12 weeks.

    Drug: Placebo

Interventions

  • MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

    Also known as: LY4268989

  • DrugPlacebo

    Matching placebo (identical appearance to MORF-057) administered orally.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)

    * The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical remission per mMCS is defined as rectal bleeding subscore of 0; a stool frequency subscore of \< or =1; and an endoscopy subscore of \< or =1 without friability.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants in Clinical Response as Determined Using the Modified Mayo Clinic Score (mMCS)

    * The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical response per mMCS is defined as decrease from baseline in the mMCS score \> or =2 points and \> or =30% from baseline, plus a decrease in rectal bleeding subscore \> or =1 or an absolute rectal bleeding subscore \< or =1.

    Time frame: Week 12

08

Results

Posted Dec 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneMORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlacebo
Started69717070
Safety analysis population70717069
Completed65686765
Not completed4335
Withdrew: Adverse event1101
Withdrew: Lack of efficacy1012
Withdrew: Lost to follow-up0001
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject2121

Outcome measures

PrimaryPercentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)

* The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical remission per mMCS is defined as rectal bleeding subscore of 0; a stool frequency subscore of \< or =1; and an endoscopy subscore of \< or =1 without friability.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)
percentage of participantsMORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlacebo
Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)31.923.917.124.3
Statistical analysis
  • MORF-057 200 mg BID vs Placebo · Risk difference (rd): 6.71 · 95% CI -7.76 to 21.18
  • MORF-057 100 mg BID vs Placebo · Risk difference (rd): -0.41 · 95% CI -13.99 to 13.17
  • MORF-057 100 mg QD-M vs Placebo · Risk difference (rd): -6.93 · 95% CI -19.74 to 5.88
SecondaryPercentage of Participants in Clinical Response as Determined Using the Modified Mayo Clinic Score (mMCS)

* The mMCS is a scoring system for assessment of ulcerative colitis activity and is a composite of Endoscopic subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration)), Stool Frequency subscore (range: 0=Normal number of stools to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The mMCS total score ranges from 0 to 9, with higher scores indicating more severe disease. * Clinical response per mMCS is defined as decrease from baseline in the mMCS score \> or =2 points and \> or =30% from baseline, plus a decrease in rectal bleeding subscore \> or =1 or an absolute rectal bleeding subscore \< or =1.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Response as Determined Using the Modified Mayo Clinic Score (mMCS)
percentage of participantsMORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlacebo
Percentage of Participants in Clinical Response as Determined Using the Modified Mayo Clinic Score (mMCS)62.353.557.154.3
Statistical analysis
  • MORF-057 200 mg BID vs Placebo · Risk difference (rd): 7.05 · 95% CI -8.77 to 22.86
  • MORF-057 100 mg BID vs Placebo · Risk difference (rd): -0.93 · 95% CI -16.74 to 14.88
  • MORF-057 100 mg QD-M vs Placebo · Risk difference (rd): 3.07 · 95% CI -12.78 to 18.92

Adverse events

Collected over Baseline to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MORF-057 200 mg BID0/70 (0%)1/70 (1.4%)9/70 (12.9%)
MORF-057 100 mg BID0/71 (0%)3/71 (4.2%)8/71 (11.3%)
MORF-057 100 mg QD-M0/70 (0%)0/70 (0%)5/70 (7.1%)
Placebo0/69 (0%)1/69 (1.4%)10/69 (14.5%)
Most frequent serious events
Most frequent serious events
EventMORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlacebo
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/700/710/701/69
Colitis ulcerativeGastrointestinal disorders1/701/710/700/69
Aspartate aminotransferase increasedInvestigations0/701/710/700/69
PneumothoraxRespiratory, thoracic and mediastinal disorders0/701/710/700/69
Most frequent other events
Most frequent other events
EventMORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlacebo
HeadacheNervous system disorders5/704/712/702/69
AnaemiaBlood and lymphatic system disorders2/702/713/704/69
NasopharyngitisInfections and infestations3/703/710/704/69

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)MORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlaceboTotal
Mean41.0 ± 17.1441.8 ± 14.3538.9 ± 13.5739.1 ± 1340.2 ± 14.57
Sex: Female, Male
Sex: Female, Male(Participants)MORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlaceboTotal
Female28323134125
Male41393936155
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlaceboTotal
Hispanic or Latino21126
Not Hispanic or Latino66706968273
Unknown or Not Reported10001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MORF-057 200 mg BIDMORF-057 100 mg BIDMORF-057 100 mg QD-MPlaceboTotal
American Indian or Alaska Native00000
Asian1411131351
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White53605757227
More than one race00000
Unknown or Not Reported20002
09

Study locations

102 sites
  • Arizona Digestive Health - Sun City
    Sun City, Arizona 85351, United States
  • Gastro Care Institute
    Lancaster, California 93534, United States
  • TLC Clinical Research Inc.
    Los Angeles, California 90048, United States
  • Innova Clinical Trials
    Coral Gables, Florida 33145, United States
  • Eminat, LLC - Miramar
    Miramar, Florida 33027, United States
  • Robert Wood Johnson University Medical School
    New Brunswick, New Jersey 08901, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Blacktown Hospital
    Blacktown, 2148, Australia
  • Concord Repatriation General Hospital
    Concord, 2139, Australia
  • Royal Brisbane and Women's Hospital
    Herston, QLD 4029, Australia
  • Fiona Stanley Hospital
    Murdoch, 6150, Australia
  • Mater Adult Hospital Brisbane
    South Brisbane, 4101, Australia
  • Order Hospital Linz Ltd. - Hospital of Sisters of Mercy
    Linz, 4010, Austria
  • Salzburg Regional Hospital
    Salzburg, 5020, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Medical Center "Rusemed" EOOD
    Rousse, 7005, Bulgaria
  • University Multiprofile Hospital for Active Treatment "ACIBADEM City Clinic"
    Sofia, 1202, Bulgaria
  • Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda
    Sofia, 1407, Bulgaria
  • Second Multiprofile Hospital for Active Treatment - Sofia
    Sofia, 2700, Bulgaria
  • PreventaMed, s.r.o.
    Olomouc, 77900, Czechia
  • Clinoxus s.r.o., Outpatient Clinic Budejovicka
    Prague, 140 00, Czechia
  • LV Venter OU
    Pärnu, 80010, Estonia
  • OU Innomedica
    Tallinn, 10117, Estonia
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • University of Tartu
    Tartu, 51014, Estonia
  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet
    Nice, 06202, France
  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
    Tbilisi, 0101, Georgia
  • Curatio, Jsc
    Tbilisi, 0114, Georgia
  • JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
    Tbilisi, 0159, Georgia
  • LTD Aversi Clinic
    Tbilisi, 0160, Georgia
  • Medical Center "CITO" Ltd.
    Tbilisi, 0179, Georgia
  • LTD The First Medical Center
    Tbilisi, 0180, Georgia
  • Charite - University Hospital Berlin
    Berlin, 10117, Germany
  • Krankenhaus Waldfriede
    Berlin, 14163, Germany
  • University Hospital Schleswig-Holstein
    Kiel, 24105, Germany
  • University Hospital Ulm
    Ulm, 89081, Germany
  • Semmelweis Medical University
    Budapest, 1083, Hungary
  • Semmelweis University, Department of Internal Medicine and Haematology, Division of Internal Medicine and Gastroenterology
    Budapest, H-1088, Hungary
  • Bugat Pal Korhaz
    Gyöngyös, 3200, Hungary
  • Fejér Megyei Szent György Egyetemi Oktató Kórház
    Székesfehérvár, 8000, Hungary
  • Fejer County St. Gyorgy University Teaching Hospital
    Székesfehérvár, H-8000, Hungary
  • Javorszky Odon Korhaz
    Vác, 2600, Hungary
  • Fortis Memorial Research Institute(FMRI)
    Gūrgaon, 122002, India
  • Gleneagles Hospital
    Hyderabad, 500004, India
  • Sawai Man Singh Medical College Hospital (SMS Hospital)
    Jaipur, 302004, India
  • S R Kalla Memorial Gastro and General Hospital
    Jaipur, 302006, India
  • Dayanand Medical College and Hospital
    Ludhiana, 141001, India
  • All India Institute of Medical Sciences
    New Delhi, 110029, India
  • Fortis Hospital
    Noida, 201301, India
  • Yashoda Hospital
    Secunderabad, 500003, India
  • SIDS Hospital and Research Centre
    Surat, 395002, India
  • Government Medical College
    Thiruvananthapuram, 695011, India
  • Shaare Zedek Medical Center, Digestive Diseases Institute
    Jerusalem, 91004, Israel
  • Kaplan Medical Center, Institute of Gastroenterology and Liver Diseases
    Rehovot, 7661041, Israel
  • Ospedale Luigi Sacco
    Milan, 20157, Italy
  • Hospital of Padova
    Padova, 35128, Italy
  • IRCCS Istituto Clinico Humanitas- Centro Malattie Infiammatorie Intestinali
    Rozzano, 20089, Italy
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • IRCCS Ospedale San Raffaele
    Segrate, 20132, Italy
  • Liepaja Regional Hospital
    Liepāja, LV-3414, Latvia
  • Digestive Diseases Center "Gastro"
    Riga, 1079, Latvia
  • Pauls Stradins Clinical Univeristy Hospital
    Riga, LV-1002, Latvia
  • Republican Panevezys Hospital
    Panevezys, 35144, Lithuania
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, LT-08406, Lithuania
  • CLINSANTE Clinical Research Centre Ewa Galczak-Nowak, Malgorzata Trzaska
    Bydgoszcz, 85-794, Poland
  • St. John Paul 2nd Municipal Hospital in Elblag
    Elblag, 82-300, Poland
  • "Vita Longa" Non-Public Healthcare Facility, Limited Liability Company
    Katowice, 40-748, Poland
  • Krakow Medical Center
    Krakow, 31-501, Poland
  • IP Clinic
    Lodz, 90-752, Poland
  • University Teaching Hospital No. 4 in Lublin
    Lublin, 20-090, Poland
  • ETG Lublin
    Lublin, 20-412, Poland
  • Twoja Przychodnia Opolskie Centrum Medyczne
    Opole, 45 819, Poland
  • EMC Medical Institute Joint Stock Company, "Certus" Private Healthcare Facility Hospital No. 1
    Poznan, 60-309, Poland
  • Twoja Przychodnia Pcm
    Poznan, 60-324, Poland
  • Endoscopy Limited Liability Company
    Sopot, 81-756, Poland
  • New health-CK, Kieltucki and partners g.p.
    Staszów, 28-200, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, 71-434, Poland
  • H-T. Medical Center
    Tychy, 43-100, Poland
  • Centrum Medyczne Reuma Park
    Warsaw, 02-665, Poland
  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, 04-501, Poland
  • EMC Medical Institute Joint Stock Company, EuroMediCare Specialist Outpatient Clinics in Wroclaw
    Wroclaw, 54-144, Poland
  • ETG Zamość
    Zamość, 22-400, Poland
  • Colentina Clinical Hospital
    Bucharest, 020125, Romania
  • Center of Diagnosis and Treatment Provita
    Bucharest, 21494, Romania
  • Zvezdara University Medical Center
    Belgrade, 11 000, Serbia
  • Clinical Hospital Center Bezanijska Kosa
    Belgrade, 11000, Serbia
  • General Hospital "Djordje Joanovic"
    Zrenjanin, 23000, Serbia
  • Cliniq s.r.o.
    Bratislava, 811 09, Slovakia
  • ENDOMED s.r.o.
    Košice, 04013, Slovakia
  • Gastro LM s.r.o.
    Prešov, 08001, Slovakia
  • Dong-A University Hospital
    Busan, 49201, South Korea
  • Yeungnam Univeristy Medical Center
    Daegu, 42415, South Korea
  • Kyung Hee University Hospital
    Seoul, 02447, South Korea
  • Changhua Christian Hospital
    Changhua, 50006, Taiwan
  • Chia-Yi Christian Hospital
    Chiayi City, 600, Taiwan
  • Tri-Service General Hospital
    Neihu Taipei, 11490, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan

Showing the first 100 of 102 sites across 21 countries. Choose a country and city above to see the rest.

10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2024, 24 months.

Results were first posted in Dec 2025, 1 year after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 24 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Nov 10, 2022
StartActual
Nov 21, 2022
Primary completionActual
Nov 28, 2024
CompletionActual
Sep 21, 2026was Aug 2026
Results first posted
Dec 15, 2025
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Study completion
Aug 2026→Sep 21, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    Study completion Aug 2026→Sep 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05611671
Responsible party
Sponsor
First posted
Nov 10, 2022
Start date
Nov 21, 2022
Primary completion
Nov 28, 2024
Completion
Sep 21, 2026
Results posted
Dec 15, 2025
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MORF-057

Start the discussion